Millennium Management’s Viking Therapeutics VKTX Stock Holding History

Millennium Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$651K	Sell	16,700 -59,000	-78%	-$1.91M	﹤0.01%	4599
2026 Q1	$2.46M	Sell	75,700 -74,300	-50%	-$2.39M	﹤0.01%	3667
2025 Q4	$5.28M	Sell	150,000 -54,600	-27%	-$1.93M	﹤0.01%	2947
2025 Q3	$5.38M	Buy	204,600 +56,400	+38%	+$1.68M	﹤0.01%	3070
2025 Q2	$3.93M	Sell	148,200 -56,800	-28%	-$1.5M	﹤0.01%	3237
2025 Q1	$4.95M	Buy	205,000 +41,600	+25%	+$1.31M	﹤0.01%	2878
2024 Q4	$6.58M	Buy	163,400 +153,400	+1,534%	+$8.75M	﹤0.01%	2578
2024 Q3	$633K	Sell	10,000 -61,600	-86%	-$3.61M	﹤0.01%	4639
2024 Q2	$3.8M	Buy	71,600 +61,400	+602%	+$4.02M	﹤0.01%	2978
2024 Q1	$836K	Buy	+10,200	New	+$454K	﹤0.01%	4454
2023 Q4	–	Sell	-114,400	Closed	-$1.27M	–	6586
2023 Q3	$1.27M	Sell	114,400 -8,600	-7%	-$123K	﹤0.01%	3993
2023 Q2	$1.99M	Sell	123,000 -212,300	-63%	-$4.45M	﹤0.01%	3486
2023 Q1	$5.58M	Sell	335,300 -111,400	-25%	-$1.15M	﹤0.01%	2508
2022 Q4	$4.2M	Buy	+446,700	New	+$1.99M	﹤0.01%	2962

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Millennium Management's VKTX Position: Q2 2026 in Review

Millennium Management increased its Viking Therapeutics (VKTX) stake by 99% in Q2 2026, buying an estimated $8M and bringing the position to 498,172 shares worth $19.4M. The position accounts for 0.01% of the portfolio, ranked #1657.

Millennium Management first reported a position in VKTX in Q4 2017 and has held it in 30 quarters since. The position peaked at $63.9M in Q1 2023. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Millennium Management held 498,172 shares of Viking Therapeutics worth $19.4M as of Q2 2026.
Millennium Management bought 247,647 Viking Therapeutics shares in Q2 2026, an estimated $8M.
Viking Therapeutics made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1657 holding.
Millennium Management first reported a position in Viking Therapeutics in Q4 2017 and has held it in 30 quarters since.
Millennium Management's Viking Therapeutics position peaked at $63.9M in Q1 2023.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.